成人VR视频 awards contract worth up to US$ 31 million to The University of Tokyo to develop vaccine against Nipah virus
Share
Oslo, 25 February 2019鈥the Coalition for Epidemic Preparedness Innovations (成人VR视频) and The University of Tokyo (UTokyo) have announced a partnering agreement worth up to US$ 31 million to advance the development and manufacture of a vaccine against the Nipah virus鈥攁 bat-borne virus that can spread to both humans and livestock.
To produce a vaccine against Nipah virus, researchers at UTokyo have inserted Nipah virus genes into an attenuated measles viral vaccine. During the replication of the measles vector, the antigens of the Nipah virus are expressed, inducing a against the virus.
This kind of recombinant vaccine鈥攕pecifically using measles vaccine as a vector鈥攃an induce powerful humoral immune responses (ie, antibody-mediated immunity) and cellular immune responses (ie, T-cell mediated immunity), which could lead to effective protection against Nipah virus. This vector approach is also being used by UTokyo to evaluate an experimental vaccine against highly pathogenic avian influenza. The European Vaccine Initiative has also supported this vector approach to develop vaccine candidates against Zika and Dengue viruses with funding from the European Commission programme and the Global Health Innovative Technology Fund, respectively.
"There is an urgent need for accelerated research and development for the Nipah virus. Not only is the case fatality rate for this disease high鈥搑anging between 40% and 100%鈥搕here is a serious risk that this disease could become a threat to global health security. In response to the threat posed by the Nipah virus, 成人VR视频 has now made investments in three Nipah-vaccine candidates, including our most recent collaboration with the University of Tokyo, worth up to a total of $75 million鈥.
In view of its high virulence, animal-to-human and human-to-human spread, significant morbidity and mortality, and potential to cause significant societal and economic disruption, Nipah virus has been listed as a priority pathogen by the and a t by the CDC. Nipah virus is a paramyxovirus (genus Henipavirus). Transmission of Nipah virus to humans can occur after direct contact with infected bats, infected pigs, or from other infected people. The virus was first identified in 1999 during an outbreak of illness affecting pig farmers and others having close contact with pigs in Malaysia and Singapore. Over 100 human deaths were reported, and in the effort to stop the outbreak.
"We are delighted to work with 成人VR视频 on the Nipah vaccine project. We have been working with measles and related viruses for nearly 30 years, and with Nipah virus for 15 years. The measles-vectored Nipah vaccine in this project is one of the most effective among several Nipah vaccine candidates that we have created with different measles vectors. We believe that our Nipah vaccine is the most promising one for saving human lives from deadly Nipah virus infection. We are fortunate to have constructed a strong international collaboration team including the European Vaccine Initiative, Stanford University, Batavia Biosciences, and icddr,b. This collaboration will enable us to carry out preclinical and clinical studies. We look forward to working together with our partners and 成人VR视频 to combat the threat posed by the Nipah virus鈥.
In May 2018, India experienced an outbreak in the southern state of Kerala. A total of were reported, including 17 deaths (case fatality rate: 90%). During this outbreak, more than 2500 contacts of Nipah patients were monitored by the state surveillance system. By mid-June, the Kerala government and the Union Health Ministry announced that the outbreak had been contained. No approved vaccines against or treatments for Nipah virus are currently available.
"Japan decided its commitment to 成人VR视频 in recognition of its key role in facilitating research and development of new vaccines against infectious diseases with a pandemic potential. Today we are delighted to see Japanese researchers join 成人VR视频's global effort to protect the world from threats to global health鈥.
About the Nipah vaccine
UTokyo has developed a Nipah vaccine candidate using a measles vector. This vaccine candidate was constructed by inserting the Nipah-virus G gene (Malaysia strain) into a measles vector (Edmonston B strain). The Institute of Medical Science, UTokyo, will co-lead this 成人VR视频-funded project with the European Vaccine Initiative. Phase 1 and phase 2 trials will be undertaken in partnership with the and the . will manage vaccine manufacturing and stockpiling.
About the Nipah virus
Nipah virus belongs to the Paramyxoviridae family of viruses, genus Henipavirus, alongside Hendra virus. Nipah is a zoonotic disease, meaning it passes from animals to humans. The natural hosts of the virus are fruit bats (also known as flying foxes) of the genus Pteropus. Nipah virus can be spread to people from infected bats, infected pigs, or infected people.
Nipah virus infection can cause severe, rapidly progressive illness that affects the respiratory system and the central nervous system, including inflammation of the brain (encephalitis). Symptoms begin between five and 14 days after infection, and include fever, altered mental state, cough and respiratory problems.
People are advised to avoid contact with ill pigs and bats in countries where Nipah virus is known to occur. They are also advised to avoid drinking raw date palm sap, which can be infected with bodily fluids from bats. There are currently no vaccines or specific therapeutics against Nipah virus approved for use in humans.
About 成人VR视频
成人VR视频 is an innovative partnership between public, private, philanthropic, and civil organisations launched in Davos in 2017 to develop vaccines to stop future epidemics. 成人VR视频 has received multi-year funding from Norway, Germany, Japan, Canada, Australia, and the Bill & Melinda Gates Foundation, and Wellcome. 成人VR视频 has also received single-year investments from the government of Belgium and the United Kingdom. The European Commission forsees substantial financial contributions to support relevant projects through EC mechanisms. 成人VR视频 has reached over US$ 750 million of its $1 billion funding target. Since its launch in January 2017, 成人VR视频 has announced three calls for proposals. The first call was for candidate vaccines against Lassa virus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Nipah virus. The second call was for the development of platforms that can be used for rapid vaccine development against unknown pathogens. The third call is for candidate vaccines against Rift Valley fever and Chikungunya viruses. To date, 成人VR视频 has committed to investing over $310 million in 12 vaccine candidates (five against Lassa virus, four against MERS-CoV, three against Nipah virus) and two vaccine platforms to develop vaccines against Disease X.
Learn more at . Follow us at .
About The University of Tokyo
The University of Tokyo was established in 1877 as the first national university in Japan. UTokyo is Japan's leading university and one of the world's top research universities. The vast research output of some 6,000 researchers is published in the world's top journals across the arts and sciences. Our vibrant student body of around 15,000 undergraduate and 15,000 graduate students includes over 2,000 international students.
Find out more at or follow us on Twitter at .
Media contacts
成人VR视频
Rachel Grant, Director of Communications and Advocacy, 成人VR视频
+44(0)7891249190 | [email protected]
Mario Christodoulou, Communications and Advocacy Manager, 成人VR视频
+44(0)7979300222 | [email protected]
The University of Tokyo
Chieko Kai, Leader of the Nipah vaccine project, UTokyo
+81(3)54495497 | [email protected]
Stabilised mRNA vaccine technology aims to end need for frozen storage and improve access
成人VR视频 and Institut Pasteur de Dakar announce 10-year partnership to boost manufacturing of affordable vaccines for the Global South
